Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 6/20 | 0.35 |
| ▸ | NPY4R | P50391 | 6/20 | 0.35 |
| ▸ | NPY1R | P25929 | 5/20 | 0.35 |
| ▸ | NPY2R | P49146 | 3/20 | 0.35 |
| ▸ | FAP | Q12884 | 2/20 | 0.34 |
| ▸ | FURIN | P09958 | 4/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | NMT2 | O60551 | 1/20 | 0.33 |
| ▸ | NMT1 | P30419 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20864068 | 1.00 | NPY5R (0.35) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL17722913 | 0.94 | NPY5R (0.37) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL20887767 | 0.92 | FURIN (0.35) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL24335031 | 0.92 | FAP (0.34) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL22668644 | 0.92 | FAP (0.34) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL23436443 | 0.92 | FAP (0.34) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL20887736 | 0.90 | FAP (0.37) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL23420959 | 0.90 | FAP (0.37) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL27421373 | 0.89 | FAP (0.36) | NPY5RNPY4RNPY1RNPY2RFAP | |
| SCHEMBL23256415 | 0.89 | PTGS1 (0.41) | NPY5RNPY4RNPY1RNPY2RFAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2020-07-09 | — | — | US | disclosed |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2019-10-17 | — | — | US | disclosed |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-08-20 | — | — | US | disclosed |
| US-10308713-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC (US) | 2019-04-11 | — | — | US | disclosed |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | ABBVIE INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180222979-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE BIOTHERAPEUTICS INC. | 2018-08-09 | — | — | US | disclosed |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | ABBVIE BIOTHERAPEUTICS INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | AbbVie Manufacturing Management Unlimited Company (IE) | 2017-12-07 | — | — | US | disclosed |
| WO-2017095805-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. (US) | 2017-06-08 | — | — | WO | disclosed |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | ABBVIE INC. | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190105329-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NPY5R 2662/4885NPY4R 3989/4885NPY1R 4099/4885 |
| US-20170151343-A1 | ANTI-huLRRC15 ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | LRRC59, LRRC47, HACD3 | NPY5R 2662/4885NPY4R 3989/4885NPY1R 4099/4885 |
| US-20200215200-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NPY5R 3964/4885NPY4R 4286/4885NPY1R 4608/4885 |
| US-20190314518-A1 | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NPY5R 3964/4885NPY4R 4286/4885NPY1R 4608/4885 |
| US-20170348429-A1 | ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | MMAB, HNMT, SHMT1 | NPY5R 3964/4885NPY4R 4286/4885NPY1R 4608/4885 |
| US-20180222979-A1 | ANTI-CS1 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | CD47, CSGALNACT1, CSE1L | NPY5R 4707/4885NPY4R 4779/4885NPY1R 4604/4885 |
| US-10308713-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | NPY5R 4707/4885NPY4R 4779/4885NPY1R 4604/4885 |
| US-10011657-B2 | Anti-CS1 antibodies and antibody drug conjugates | CD47, CSGALNACT1, CSE1L | NPY5R 4707/4885NPY4R 4779/4885NPY1R 4604/4885 |
| US-10383948-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | NPY5R 3964/4885NPY4R 4286/4885NPY1R 4608/4885 |
| US-10188660-B2 | Anti-huLRRC15 antibody drug conjugates and methods for their use | LRRC59, LRRC47, HACD3 | NPY5R 2662/4885NPY4R 3989/4885NPY1R 4099/4885 |
| US-10603389-B2 | Anti-cMet antibody drug conjugates and methods for their use | MMAB, HNMT, SHMT1 | NPY5R 3964/4885NPY4R 4286/4885NPY1R 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.